Drug reference
ruxolitinib
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Oncology (Anti Neoplastics)
Mechanism of action
Kinase inhibitor; inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function
Common side effects
- Neutropenia
- Anemia
- Dizziness
- Thrombocytopenia
- Increased ALT
- Bruising
Related conditions
Frequently asked questions
What drug class is ruxolitinib?
ruxolitinib belongs to: Oncology.
How does ruxolitinib work?
Kinase inhibitor; inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function
What are the common side effects of ruxolitinib?
Neutropenia, Anemia, Dizziness, Thrombocytopenia, Increased ALT, Bruising
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.